Visceral leishmaniasis in an HIV-infected patient

Infectious Diseases in Clinical Practice

Volumn 14, Issue 2, 2006, Pages 119-122

  Madariaga, Miguel G ^a,c   Kohl, Shane K ^b   Starlin, Richard ^a   Smith, Philip W ^a   West, William W ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIRETROVIRUS AGENT; IVERMECTIN; MEGLUMINE ANTIMONATE; MILTEFOSINE; STIBOGLUCONATE SODIUM;

ADULT; AFRICA; ARTICLE; CASE REPORT; CD4 LYMPHOCYTE COUNT; FEVER; HEPATOSPLENOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; MALE; SOUTHERN EUROPE; STRONGYLOIDIASIS; VISCERAL LEISHMANIASIS;

EID: 33646529333     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.idc.0000198459.63367.39     Document Type: Article

References (26)

1. World Health Organization. WHO Report on Global Surveillance of Epidemic-prone Infectious Diseases. January 2000. Available at: http://www.who.int/emc-documents/surveillance/docs/whocdscsrisr2001.html/ Tableofcontents/about.htm. Accessed April 15, 2005.
2. Leishmania/HIV co-infection. Epidemiological analysis of 692 retrospective cases. Wkly Epidemiol Rec. 1997;72:49-54.
3. Lopez-Velez R, Perez-Molina JA, Guerrero A, et al. Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg. 1998;58:436-443.
4. Pintado V, Martin-Rabadan P, Rivera ML, et al. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore). 2001;80:54-73.
5. Magill AJ, Grogl M, Gasser RA Jr, et al. Visceral infection caused by Leishmania tropica in veterans of Operation Desert Storm. N Engl J Med. 1993;328:1383-1387.
6. Parkas V, Godwin J, Murray HW. Kala-azar comes to New York. Arch Intern Med. 1997;157:921-923.
7. Wang J, Vanley C, Miyamoto E, et al. Coinfection of visceral leishmaniasis and Mycobacterium in a patient with acquired immunodeficiency syndrome. Arch Pathol Lab Med. 1999;123:835-837.
8. Two cases of visceral leishmaniasis in U.S. military personnel - Afghanistan, 2002-2004. MMWR Morb Mortal Wkly Rep. 2004;53:265-268.
9. Halsey ES, Bryce LM, Wortmann GW, et al. Visceral leishmaniasis in a soldier returning from Operation Enduring Freedom. Mil Med. 2004;169:699-701.
10. Anonymous. Canine leishmaniasis confirmed in 21 states. J Am Vet Med Assoc. 2000;217:1129.
11. Eddlestone SM. Visceral leishmaniasis in a dog from Maryland. J Am Vet Med Assoc. 2000;217:1686-1688.
12. Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev. 1997;10:298-319.
13. Albrecht H, Sobottka I, Emminger C, et al. Visceral leishmaniasis emerging as an important opportunistic infection in HIV-infected persons living in areas nonendemic for Leishmania donovani. Arch Pathol Lab Med. 1996;120:189-198.
14. Zhao C, Papadopoulou B, Tremblay MJ. Leishmania infantum enhances human immunodeficiency virus type-1 replication in primary human macrophages through a complex cytokine network. Clin Immunol. 2004;113:81-88.
15. Tremblay M, Olivier M, Bernier R. Leishmania and the pathogenesis of HIV infection. Parasitol Today. 1996;12:257.
16. Bernier R, Turco SJ, Olivier M, et al. Activation of human immunodeficiency virus type 1 in monocytoid cells by the protozoan parasite Leishmania donovani. J Virol. 1995;69:7282-7285.
17. Lopez-Velez R, Laguna F, Alvar J, et al. Parasitic culture of buffy coat for diagnosis of visceral leishmaniasis in human immunodeficiency virus-infected patients. J Clin Microbiol. 1995;33:937-939.
18. Butch AW. Dilution protocols for detection of hook effects/prozone phenomenon. Clin Chem. 2000;46:1719-1721.
19. Siddig M, Ghalib H, Shillington DC, et al. Visceral leishmaniasis in the Sudan: comparative parasitological methods of diagnosis. Trans R Soc Trop Med Hyg. 1988;82:66-68.
20. Bossolasco S, Gaiera G, Olchini D, et al. Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol. 2003;41:5080-5084.
21. Pizzuto M, Piazza M, Senese D, et al. Role of PCR in diagnosis and prognosis of visceral leishmaniasis in patients coinfected with human immunodeficiency virus type 1. J Clin Microbiol. 2001;39:357-361.
22. Laguna F, Videla S, Jimenez-Mejias ME, et al. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemother. 2003;52:464-468.
23. Sindermann H, Engel KR, Fischer C, et al. Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis. 2004;39:1520-1523.
24. de la Rosa R, Pineda JA, Delgado J, et al. Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis. 2001;32:633-635.
25. Berry A, Abraham B, Dereure J, et al. Two case reports of symptomatic visceral leishmaniasis in AIDS patients concomitant with immune reconstitution due to antiretroviral therapy. Scand J Infect Dis. 2004;36:225-227.
26. Lopez-Velez R, Videla S, Marquez M, et al. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother. 2004;53:540-543.